Showing 4481-4490 of 8849 results for "".
- Mblue Labs Introduces First Anti-Aging, Coral Safe Sunscreen with Methylene Bluehttps://practicaldermatology.com/news/mblue-labs-introduces-first-anti-aging-coral-safe-sunscreen-with-methylene-blue/2461094/Mblue Labs is launching Bluevado SunFix, the first sunscreen with Methylene Blue, a centuryold medicine that is also safe for coral reefs and also delays skin aging. Fully 80 percent of today’s sunscreens use Oxybenzone as a chemical UV blocker, despite studies that have show
- Vial Names Dr. Mark Lebwohl to Scientific Advisory Boardhttps://practicaldermatology.com/news/vial-names-dr-mark-lebwohl-to-scientific-advisory-board/2461091/The Vial Dermatology CRO has added Mark Lebwohl, MD, MPH to the Vial Scientific Advisory Board. Dr. Lebwohl will lend his expertise to the Vial CRO team and leading sponsors working to advance the Dermatology research field.<
- US Senate Passes Dr. Lorna Breen Acthttps://practicaldermatology.com/news/us-senate-passes-lorna-breen-act/2461090/The US Senate has passed the bipartisan Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667). The bill previously was passed by the US House of Representatives, and now goes to President Biden to be signed into law. Once signed, the Dr. Lorna Breen Health Care
- Acne Breakthrough: Fat Cells in the Skin May Help Fight Acnehttps://practicaldermatology.com/news/fat-cells-in-the-skin-may-help-fight-acne/2461080/New research suggests that fibroblasts outside of hair follicles play a larger role in acne development. Fibroblasts produce an antimicrobial peptide called cathelicidin in skin. To counter an infection within a hair follicle, the surrounding skin undergoes a process called reactiv
- GW Dermatology, La Roche-Posay Establish GW Skin Cancer Research Acceleration Fundhttps://practicaldermatology.com/news/gw-dermatology-la-roche-posay-establish-gw-skin-cancer-research-acceleration-fund/2461074/The Department of Dermatology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS) has partnered with La Roche-Posay to establish the La Roche-Posay Skin Cancer Research Acceleration Fund at GW. The $50,000 gift will be used to support the growth
- Neutrogena Announces New "Heroes of Skin Health Equity" Initiativehttps://practicaldermatology.com/news/neutrogena-announces-new-heroes-of-skin-health-equity-initiative/2461057/Neutrogena is launching its new Heroes of Skin Health Equity initiative, the brand’s latest effort aimed at closing the gap to skin health equity for those with Black and brown skin. The brand will publicly recognize the work of individuals who are striving to make
- Desert Harvest's Aloe Glide Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/desert-harvests-aloe-glide-receives-nea-seal-of-acceptance/2461056/Desert Harvest’s Aloe Glide has received the National Eczema Association (NEA) Seal of Acceptance, making it the first sexual lubricant to earn this seal. The NEA Seal appears on products approved by the association to help consumers identify and choose products that are suitable
- Vial to Host Advisory Boardhttps://practicaldermatology.com/news/vial-to-host-advisory-board/2461038/Vial is hosting an Advisory Board with leading research sites to discuss the challenges in clinical research. Launched in conjunction with the 2022 Winter Clinical Dermatology conference, the meeting will focus on improving speed and quality of trials in dermatology. The Vial executive
- Vial Launches Dermatology CROhttps://practicaldermatology.com/news/vial-launches-dermatology-cro/2461031/Vial has launched the Vial Dermatology CRO, dubbing it “The CRO Built for Sponsors.” The San Francisco-based company will rely on a clinic network of more than 35 dermatology clinics across the country to re
- LEO Pharma's Adbry Approved for Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-approved-for-moderate-to-severe-ad/2461020/FDA has approved Adbry™ (tralokinumab-ldrm) from LEO Pharma Inc. for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the